In the phase II ATLANTIC trial of durvalumab in heavily pretreated patients with NSCLC, a subgroup analysis was dedicated to those with EGFR- and anaplastic lymphoma kinase (ALK)-positive disease (n = 111). This evidence concerns the gene EGFR and non-small cell lung carcinoma.